Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial
Primary result · Time in range 3.9-10.0 mmol l-1Result — go to the resultMean increase 4.8 percentage pointsAuthors' conclusion
We conclude that semaglutide improves glycemic control with automated insulin delivery compared to placebo.
Study context
- Population
- Adults with T1D using AID24 completed
- Participants
- 28 adults
- Comparison
- Semaglutide vs placebo as adjunct to AID
- Primary endpoint
- Percentage of time in target glucose range 3.9-10.0 mmol l-1
- Follow-up
- Last 4 weeks of each intervention
Methodological detailsdouble-blind, crossover
- Double-blind
- Crossover
Primary result
Time in range 3.9-10.0 mmol l-1
Mean increase
4.8 percentage points
P = 0.006
As reported in the abstract
Further findings
| Outcome | P value |
|---|---|
| Time below 3.9 mmol l-1 | P = 0.19 |
| Time below 3.0 mmol l-1 | P = 0.65 |
Time below 3.9 mmol l-1
- Not increased with semaglutide vs placebo
Time below 3.0 mmol l-1
- Not increased with semaglutide vs placebo
Safety
- Episodes of recurrent euglycemic ketosis without acidosis during semaglutide use
- 2
- Time below 3.9 mmol l-1 not increased with semaglutide vs placebo
- P = 0.19
- Time below 3.0 mmol l-1 not increased with semaglutide vs placebo
- P = 0.65
- No DKA or severe hypoglycaemia occurred during any of the interventions
Original publication
Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nat Med. Published 10 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →